c******d
发帖数: 171 | 3 top名单出炉
Baker Bro's, although they've gotten quite big in terms of AUM that they
have diversified to primary market placements. Range of biotech plays from
small to large, hard to pinpoint an exact area they are focused on, but good
track record nonetheless.
Broadfin Capital comes to mind, strong emphasis on small-mid cap medtech
plays.
Perspective Advisors did well in 2015. From their holdings they appear
focused on small-mid caps in niche disease areas with low clinical risk and
unsaturated markets, something I personally like as well.
Dafna Capital, but they are relatively small in terms of AUM compared to the
first 3. Also heavily weighted towards small caps niche market spaces.
EcoR1 Capital.
Visium Asset Management, though they've diversified and have exposure to
more than just healthcare/biotech.
RA Capital has a very interesting, publicized research system and a teams
built around pure life science backgrounds. Think financial models with a
life science twist to it. |
